Business context and reporting period
Orthofix International N.V. (the registrant named in this filing; the request identifies Orthofix Medical Inc.) reported the quarter and six months ended June 30, 2014. The filing was signed March 30, 2015, and was filed alongside related amendments and delayed quarterly reports following a further restatement. Orthofix operates in BioStim, Biologics, Extremity Fixation and Spine Fixation.
Financial performance
Amounts are U.S. dollars; financial figures are in millions unless noted. 2013 comparative results are restated.
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Net sales | $101.0 | $97.6 | $201.0 | $199.9 |
| Gross profit / margin | $75.6 / 74.8% | $75.8 / 77.6% | $148.8 / 74.0% | $152.2 / 76.1% |
| Operating income | $6.7 | $6.9 | $6.7 | $13.0 |
| Continuing-operations income | $3.3 | $2.0 | $1.3 | $7.9 |
| Net income (loss) | $(0.7) | $(3.0) | $(3.2) | $0.4 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $17.9 | $34.1 |
Q2 sales increased 3% year over year; six-month sales increased about 0.5%. For the six-month period, higher Extremity Fixation sales were offset in part by declines in Spine Fixation. Q2 segment growth was strongest in Extremity Fixation (+18% reported); Spine Fixation declined 13%. Six-month operating income fell despite nearly flat sales, reflecting lower gross profit and $10.6 million of accounting-review and restatement costs.
Liquidity, debt and cash flow
At June 30, cash and cash equivalents were $28.9 million and restricted cash was $45.2 million, for $74.2 million combined. Restricted cash was subject to credit-agreement restrictions. Current assets were $292.7 million and current liabilities $83.1 million. Long-term debt was $20.0 million, outstanding under a secured revolving facility, at a 2.7% effective rate; the balance was due August 30, 2015. The filing cited $180 million of remaining revolving capacity and an unused Italian credit line of about $8 million. Operating cash flow fell to $17.9 million from $34.1 million year over year. Capital expenditures were $6.3 million; investing cash use was $6.2 million. The company reported improved receivables collection and inventory turns.
Material changes, outlook and risks
- Further restatement and controls: The company identified additional errors involving patient co-pay/self-pay revenue recognition, bad-debt and accounts-receivable reserves, inventory reserves and existence, intercompany profit eliminations, and manual journal entries. Previously filed statements for 2011–2013 and Q1 2014 were deemed not reliable and restated. Restated Q2 2013 net sales were $97.6 million and net loss was $3.0 million; the filing’s restatement tables show operating income reduced from $8.8 million originally reported to $6.9 million.
- Control deficiencies: Management concluded disclosure controls and internal control over financial reporting were ineffective as of June 30, 2014, citing material weaknesses in revenue recognition, receivables reserves, inventory reserves and existence, foreign-subsidiary oversight, and manual journal entries. Remediation was ongoing and not complete.
- Operating commentary: Management attributed Q2 sales gains to BioStim sales-force improvements, Biologics channel expansion and product mix, and Extremity Fixation launches. Spine Fixation weakness reflected sales-network restructuring. Gross-margin pressure reflected product and channel mix, Brazil sales-force rebuilding, and inventory shrinkage and reserve adjustments. G&A rose partly due to control remediation and process-improvement investments.
- Unusual items and contingencies: Restatement-related charges were $2.3 million in Q2 and $10.6 million year to date. Discontinued operations included Breg-related product-liability and legal costs, net of tax, of $3.9 million in Q2 and $4.5 million year to date. The company disclosed settlements, ongoing litigation and investigations, possible SEC enforcement action, securities litigation, and a review of alleged improper payments involving its Brazil subsidiary.
- Credit and other risks: Lenders granted waivers related to delayed financial statements and covenant certificates; failure to meet waiver or credit-agreement requirements could trigger default and materially harm the company. The filing also cited Nasdaq listing-rule matters, reimbursement and regulatory changes, competition, foreign-exchange exposure, and compliance obligations. No formal financial guidance is provided.
Most important facts for investors to verify
- Review the contemporaneous 2013 Form 10-K/A, Q1 2014 Form 10-Q/A and Q3 2014 Form 10-Q for the complete restated history and reconciliation of errors.
- Track whether the disclosed material weaknesses were remediated and whether subsequent filings report effective controls.
- Confirm the status and terms of the revolving credit facility, lender waivers, covenant compliance and restricted cash availability.
- Assess whether Spine Fixation sales recover and whether margin pressure, inventory reserves and Brazil channel disruption persist.
- Monitor Breg indemnification and litigation exposure, the Brazil-related review, and other disclosed legal and regulatory matters.